newsfilter
← Latest News
GlobeNewswire·

Spyre Therapeutics Announces Grants of Inducement Awards

  • Spyre Therapeutics' Compensation Committee approved equity inducement awards consisting of 11,138 stock options & 3,195 restricted stock units (RSUs) for two non-executive employees.
  • The awards were granted on November 2, 2026, under the 2018 Equity Inducement Plan & were material to the employees' acceptance of employment per Nasdaq Listing Rule 5635(c)(4).
  • Stock options have a 10-year term with an exercise price of $95.51 based on the November 2 closing price.
  • Option vesting begins on the first anniversary of the start date with 1/4 of shares exercisable, followed by monthly vesting of 1/48 of shares thereafter.
  • RSUs vest on the next November 15 anniversary occurring on or after the start date, with 1/4 of shares vesting each anniversary.
  • Both award types require continuous service with Spyre through their respective vesting dates.
  • Spyre is a clinical-stage biotechnology company developing therapies for immunology, including extended half-life antibodies targeting α4β7, TL1A, IL-23, & IL-17A/F.
Company
Spyre Therapeutics, Inc.
Keywords
Nasdaq:SYRE, Spyre Therapeutics, Inc.